Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka)

Țară: Uniunea Europeană

Limbă: letonă

Sursă: EMA (European Medicines Agency)

Prospect Prospect (PIL)
17-12-2021

Ingredient activ:

lenalidomide hydrochloride monohydrate

Disponibil de la:

Krka, d.d., Novo mesto 

Codul ATC:

L04AX04

INN (nume internaţional):

lenalidomide

Grupul Terapeutică:

Imūnsupresanti

Zonă Terapeutică:

Multiple Myeloma; Lymphoma, Follicular

Indicații terapeutice:

Multiple myelomaLenalidomide krka d. Novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Lenalidomide krka d. Novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ir norādīts ārstēšanai pieaugušiem pacientiem ar iepriekš neārstētiem multiplā mieloma, kas nav tiesīgi transplantātu. Lenalidomide krka d. Novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Follicular lymphomaLenalidomide krka d. Novo mesto in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a). Multiple myelomaLenalidomide krka d. Novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Lenalidomide krka d. Novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ir norādīts ārstēšanai pieaugušiem pacientiem ar iepriekš neārstētiem multiplā mieloma, kas nav tiesīgi transplantātu. Lenalidomide krka d. Novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Follicular lymphomaLenalidomide krka d. Novo mesto in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).

Rezumat produs:

Revision: 3

Statutul autorizaţiei:

Autorizēts

Data de autorizare:

2021-02-11

Prospect

                                79
B. LIETOŠANAS INSTRUKCIJA
80
LIETOŠANAS INSTRUKCIJA: INFORMĀCIJA PACIENTAM
LENALIDOMIDE KRKA D.D. NOVO MESTO 2,5 MG CIETĀS KAPSULAS
LENALIDOMIDE KRKA D.D. NOVO MESTO 5 MG CIETĀS KAPSULAS
LENALIDOMIDE KRKA D.D. NOVO MESTO 7,5 MG CIETĀS KAPSULAS
LENALIDOMIDE KRKA D.D. NOVO MESTO 10 MG CIETĀS KAPSULAS
LENALIDOMIDE KRKA D.D. NOVO MESTO 15 MG CIETĀS KAPSULAS
LENALIDOMIDE KRKA D.D. NOVO MESTO 20 MG CIETĀS KAPSULAS
LENALIDOMIDE KRKA D.D. NOVO MESTO 25 MG CIETĀS KAPSULAS
lenalidomide
PIRMS ZĀĻU LIETOŠANAS UZMANĪGI IZLASIET VISU INSTRUKCIJU, JO TĀ
SATUR JUMS SVARĪGU INFORMĀCIJU.
-
Saglabājiet šo instrukciju! Iespējams, ka vēlāk to vajadzēs
pārlasīt.
-
Ja Jums rodas jebkādi jautājumi, vaicājiet ārstam vai farmaceitam.
-
Šīs zāles ir parakstītas tikai Jums. Nedodiet tās citiem. Tās
var nodarīt ļaunumu pat tad, ja šiem
cilvēkiem ir līdzīgas slimības pazīmes.
-
Ja Jums rodas jebkādas blakusparādības, konsultējieties ar ārstu
vai farmaceitu. Tas attiecas arī
uz iespējamām blakusparādībām, kas nav minētas šajā
instrukcijā. Skatīt 4. punktu.
ŠAJĀ INSTRUKCIJĀ VARAT UZZINĀT
1.
Kas ir Lenalidomide Krka d.d. Novo mesto un kādam nolūkam to lieto
2.
Kas Jums jāzina pirms Lenalidomide Krka d.d. Novo mesto lietošanas
3.
Kā lietot Lenalidomide Krka d.d. Novo mesto
4.
Iespējamās blakusparādības
5
Kā uzglabāt Lenalidomide Krka d.d. Novo mesto
6.
Iepakojuma saturs un cita informācija
1.
KAS IR LENALIDOMIDE KRKA D.D. NOVO MESTO UN KĀDAM NOLŪKAM TO LIETO
KAS IR LENALIDOMIDE KRKA D.D. NOVO MESTO
Lenalidomide Krka d.d. Novo mesto satur aktīvo vielu lenalidomīdu.
Šīs zāles pieder zāļu grupai, kas
ietekmē Jūsu imūnās sistēmas darbību.
KĀDAM NOLŪKAM LENALIDOMIDE KRKA D.D. NOVO MESTO LIETO
Lenalidomide Krka d.d. Novo mesto lieto, lai ārstētu pieaugušos ar:
-
multiplo mielomu;
-
folikulāru limfomu.
MULTIPLĀ MIELOMA
Multiplā mieloma ir ļaundabīga audzēja veids, kas ietekmē
noteikta veida baltās asins šūnas, tā sauktās
plazmas šūnas. Šīs 
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
I PIELIKUMS
ZĀĻU APRAKSTS
2
1.
ZĀĻU NOSAUKUMS
Lenalidomide Krka d.d. Novo mesto 2,5 mg cietās kapsulas
Lenalidomide Krka d.d. Novo mesto 5 mg cietās kapsulas
Lenalidomide Krka d.d. Novo mesto 7,5 mg cietās kapsulas
Lenalidomide Krka d.d. Novo mesto 10 mg cietās kapsulas
Lenalidomide Krka d.d. Novo mesto 15 mg cietās kapsulas
Lenalidomide Krka d.d. Novo mesto 20 mg cietās kapsulas
Lenalidomide Krka d.d. Novo mesto 25 mg cietās kapsulas
2.
KVALITATĪVAIS UN KVANTITATĪVAIS SASTĀVS
Katra cietā kapsula satur lenalidomīda hidrohlorīda monohidrātu,
kas atbilst 2,5 mg, 5 mg, 7,5 mg,
10 mg, 15 mg, 20 mg vai 25 mg lenalidomīda (_lenalidomide_).
Pilnu palīgvielu sarakstu skatīt 6.1. apakšpunktā.
3.
ZĀĻU FORMA
Cietā kapsula (kapsula)
Lenalidomide Krka d.d. Novo mesto 2,5 mg cietās kapsulas
Kapsulas vāciņš ir zaļš, kapsulas korpuss ir zaļš ar uzdrukātu
melnu zīmi 2.5. Kapsulas saturs ir balts
līdz dzelteni balts vai līdz brūni balts pulveris. Cietās kapsulas
izmērs: 4, garums 14 ± 1 mm.
Lenalidomide Krka d.d. Novo mesto 5 mg cietās kapsulas
Kapsulas vāciņš ir zils, kapsulas korpuss ir zils ar uzdrukātu
melnu zīmi 5. Kapsulas saturs ir balts līdz
dzelteni balts vai līdz brūni balts pulveris. Cietās kapsulas
izmērs: 2, garums 18 ± 1 mm.
Lenalidomide Krka d.d. Novo mesto 7,5 mg cietās kapsulas
Kapsulas vāciņš ir brūns, kapsulas korpuss ir brūns ar uzdrukātu
baltu zīmi 7.5. Kapsulas saturs ir balts
līdz dzelteni balts vai līdz brūni balts pulveris. Cietās kapsulas
izmērs: 1, garums 19 ± 1 mm.
Lenalidomide Krka d.d. Novo mesto 10 mg cietās kapsulas
Kapsulas vāciņš ir zaļš, kapsulas korpuss ir brūns ar uzdrukātu
baltu zīmi 10. Kapsulas saturs ir balts
līdz dzelteni balts vai līdz brūni balts pulveris. Cietās kapsulas
izmērs: 0, garums 21 ± 1 mm.
Lenalidomide Krka d.d. Novo mesto 15 mg cietās kapsulas
Kapsulas vāciņš ir brūns, kapsulas korpuss ir zils ar uzdrukātu
melnu zīmi 15. Kapsulas saturs ir balts
līdz dzelteni balts vai līdz brūni ba
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului bulgară 17-12-2021
Raport public de evaluare Raport public de evaluare bulgară 31-08-2021
Prospect Prospect spaniolă 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului spaniolă 17-12-2021
Raport public de evaluare Raport public de evaluare spaniolă 31-08-2021
Prospect Prospect cehă 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului cehă 17-12-2021
Raport public de evaluare Raport public de evaluare cehă 31-08-2021
Prospect Prospect daneză 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului daneză 17-12-2021
Raport public de evaluare Raport public de evaluare daneză 31-08-2021
Prospect Prospect germană 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului germană 17-12-2021
Raport public de evaluare Raport public de evaluare germană 31-08-2021
Prospect Prospect estoniană 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului estoniană 17-12-2021
Raport public de evaluare Raport public de evaluare estoniană 31-08-2021
Prospect Prospect greacă 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului greacă 17-12-2021
Raport public de evaluare Raport public de evaluare greacă 31-08-2021
Prospect Prospect engleză 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului engleză 17-12-2021
Raport public de evaluare Raport public de evaluare engleză 31-08-2021
Prospect Prospect franceză 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului franceză 17-12-2021
Raport public de evaluare Raport public de evaluare franceză 31-08-2021
Prospect Prospect italiană 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului italiană 17-12-2021
Raport public de evaluare Raport public de evaluare italiană 31-08-2021
Prospect Prospect lituaniană 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului lituaniană 17-12-2021
Raport public de evaluare Raport public de evaluare lituaniană 31-08-2021
Prospect Prospect maghiară 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului maghiară 17-12-2021
Raport public de evaluare Raport public de evaluare maghiară 31-08-2021
Prospect Prospect malteză 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului malteză 17-12-2021
Raport public de evaluare Raport public de evaluare malteză 31-08-2021
Prospect Prospect olandeză 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului olandeză 17-12-2021
Raport public de evaluare Raport public de evaluare olandeză 31-08-2021
Prospect Prospect poloneză 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului poloneză 17-12-2021
Raport public de evaluare Raport public de evaluare poloneză 31-08-2021
Prospect Prospect portugheză 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului portugheză 17-12-2021
Raport public de evaluare Raport public de evaluare portugheză 31-08-2021
Prospect Prospect română 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului română 17-12-2021
Raport public de evaluare Raport public de evaluare română 31-08-2021
Prospect Prospect slovacă 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului slovacă 17-12-2021
Raport public de evaluare Raport public de evaluare slovacă 31-08-2021
Prospect Prospect slovenă 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului slovenă 17-12-2021
Raport public de evaluare Raport public de evaluare slovenă 31-08-2021
Prospect Prospect finlandeză 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului finlandeză 17-12-2021
Raport public de evaluare Raport public de evaluare finlandeză 31-08-2021
Prospect Prospect suedeză 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului suedeză 17-12-2021
Raport public de evaluare Raport public de evaluare suedeză 31-08-2021
Prospect Prospect norvegiană 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului norvegiană 17-12-2021
Prospect Prospect islandeză 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului islandeză 17-12-2021
Prospect Prospect croată 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului croată 17-12-2021
Raport public de evaluare Raport public de evaluare croată 31-08-2021